Andersen-Tawil Syndrome Market Gains Ground with Government Incentives Towards Rare Disease Treatments: Fact.MR

Major players in the Andersen-Tawil syndrome industry leverage the growing global interest in personalized medicine for non-standardized treatments.

Fact.MR, Rockville MD: Market research firm Fact.MR’s has published a report on the Andersen-Tawil syndrome market has estimated positive prospects of growth in the near future. The resumption of elective medical treatment procedures in 2021 as the covid-19 pandemic subsides, will support recovery of demand arising in the industry. Further, removal of restrictions on research activities associated with rare diseases, will generate major opportunities for Andersen-Tawil syndrome treatment options in the years ahead.

According to the National Organization for Rare Disorders, the Andersen-Tawil syndrome affects male and female demographics equally. However, only around 100 cases overall have been reported in global medical literature. Diseases such as thyrotoxic periodic paralysis, hypokalemic periodic paralysis, and hyperkalemic period paralysis display similar symptoms. Consequently, accurate diagnosis is considered as major challenge among market players.

Some of the more prominent diagnostic and treatment options include potassium supplements, molecular genetic testing, voluntary muscle contraction exercises, Holter monitoring and electrocardiograms. Owing to unique symptoms among individual patients, treatments are likely to remain non-standardized for the foreseeable future.

“Increased government funding efforts aimed towards improving diagnostic procedures is expected to generate lucrative opportunities for the participants in the Andersen-Tawil syndrome market. Non-profit organizations such as Periodic Paralysis International, Muscular Dystrophy UK, Sudden Arrhythmia Death Syndromes Foundation, and Periodic Paralysis Association, are playing key roles in raising awareness positively influencing market developments,” comments a Fact.MR analyst.

Request a report sample to gain detailed insights at

Key Takeaways from Fact.MR’s Andersen-Tawil Syndrome Market

  • Beta blocker treatments are projected to reflect faster growth on the back of treatment efficacy and relatively lower costs.
  • Genetic tests will hold larger market share owing to higher levels of accuracy in diagnostic procedures.
  • Online pharmacies are rapidly gaining traction, with higher levels of internet penetration and ease of product access to patients.
  • The United States accounts for significant market share owing to high numbers of insurance payers and a vast private health sector.
  • Economic growth and investments into healthcare infrastructure support growth in China and India.

Andersen-Tawil Syndrome Market – Prominent Drivers

  • Easy international access to data on the Andersen-Tawil syndrome in recent years is supporting associated research efforts.
  • Growing government investments and incentives towards rare disease research supports growth in the market.
  • Growing involvement of private and public organizations supporting treatment and raising awareness will positively influence future developments.

Andersen-Tawil Syndrome Market– Key Restraints

  • Low prevalence of the Andersen-Tawil syndrome and lack of awareness remains a key problem hurting market players.
  • High risk of misdiagnosis and undiagnosed cases continue as prominent issues in the industry.
  • High costs associated to rare disease research will hold back innovations and growth prospects.

Discover more about the Andersen-Tawil syndrome market with figures data tables and table of contents. You can also find detailed market segmentation at

Competitive Landscape

Leading players in the Andersen-Tawil syndrome market include but are not limited to Mylan N.V., Teva Pharmaceuticals Ltd., Novartis AG, Zydus Pharmaceuticals Inc., Advanz Pharmaceuticals, and Sun Pharmaceutical Industries Ltd.

Leading players in the industry are encouraging research & development efforts in addition to strategic mergers and acquisitions to widen the scope of applications and consolidating their position in the market.

In April 2021, Teva Pharmaceuticals was acquired by Karo Pharma Aktiebolag with the aim of gaining the European OTC brand portfolios and drug research including rare disease solutions. Also, Sun Pharmaceutical Industries Ltd. announced the acquisition of 66% ownership interest in Trikaal Mediinfotech, and AWACS, through its subsidiary ABCD Technologies LLP.

More Insights on the Andersen-Tawil syndrome Market

In its latest report, Fact.MR offers unbiased analysis of the global Andersen-Tawil syndrome market. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of disease type (type 1 and type 2), drug class (carbonic anhydrate inhibitors, acetazolemaide, dichlorpenamide, antiarrhythmic drugs, and beta blockers), and distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies) across seven regions (North America, Latin America, Europe, East Asia, South Asia, Oceania, and Middle East & Africa).

Request For No-Obligation Table Of Content

Explore Fact.MR’s Coverage on the Healthcare Domain

Toxic Shock Syndrome Treatment Market: A recent study by Fact.MR on the toxic shock syndrome treatment market offers a 8-year forecast for 2018 to 2026. The study analyzes key trends that are currently determining the growth of the market. This report covers vital dynamics, including drivers, restraints, and opportunities for leading market players along with key stakeholders and emerging players.

Angelman Syndrome Treatment Market: Fact.MR’s extensive coverage on the Angelman syndrome treatment market offers in-depth insights about the prominent growth dynamics that are likely to aid expansion of prospects in the near future. Data has been presented in the form of key segments across prominent geographies, along with important information concerning key manufacturers operating within the landscape.

Goodpasture Syndrome Treatment Market: The global good pasture syndrome treatment market study published by Fact.MR offers an unbiased analysis of the prominent drivers, opportunities and trends expected to shape future expansion outlook. The report provides a comprehensive assessment on the prominent segments and geographies which are likely to benefit market players in coming years.  

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.    

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Follow Us: LinkedIn | Twitter
Market Intelligence Services:
Source: Fact.MR

Back to news